NetworkNewsBreaks

FridayFeb 07, 2020 12:53 pm

NetworkNewsBreaks – Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report

Satsuma Pharmaceuticals (NASDAQ: STSA) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are BUY rated on Satsuma given the potential we see for STS101 in the acute treatment of migraines. Phase 3 data is expected in 2H 2020, with regulatory filing in late 2021 and potential market entry in late 2022/early 2023. We see STS101 as a differentiated asset delivering dihydroergotaminemesylate (‘DHE’) intranasally that can be used by patients who do not respond to current treatment options. We estimate probability-adjusted sales of ~$300MM in 2028 along with a 70%…

Continue Reading

FridayFeb 07, 2020 12:28 pm

NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Featured in Updated Research Report by Zacks SCR

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Zacks Small Cap Research ("Zacks SCR") has released an updated research report in its on-going coverage on the Company. Copies of the new Zacks SCR report are available via the following link: http://nnw.fm/8aWe3 To view the full press release, visit http://nnw.fm/M7yQP About Pressure BioSciences Inc. Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products…

Continue Reading

FridayFeb 07, 2020 11:59 am

NetworkNewsBreaks – FFCON20: RISE to Gather World-Class Speakers to Drive Lively Debate and Thought-Provoking Discussions in Fintech

The National Crowdfunding & Fintech Association (NCFA Canada) and Toronto Finance International (“TFI”) will co-host the sixth annual Fintech & Funding Conference and Expo (FFCON20: RISE). The event, which is designed to forge crucial relationships between entrepreneurs, investors and major financial stakeholders, is slated to take place in Toronto on March 23–24, 2020. FFCON has gained a reputation for gathering world-class speakers who share new ideas and insight within the fintech space and drive lively debate and thought-provoking discussions. “We have the opportunity to leverage North America’s second-largest financial center, combined with its third-largest tech cluster, and use this momentum…

Continue Reading

FridayFeb 07, 2020 11:42 am

NetworkNewsBreaks – Revance Therapeutics, Inc. (NASDAQ: RVNC) Announces FDA Acceptance of Biologics License Application for DAXI in Treatment of Glabellar Lines

Revance Therapeutics (NASDAQ: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (“DAXI”), today announced the U.S. Food and Drug Administration’s (“FDA”) acceptance for review of the Biologics License Application (“BLA”) for DAXI in the treatment of moderate to severe glabellar (“frown”) lines. Per the update, FDA stated in its correspondence that no potential filing review issues were identified and set an action date of November 25, 2020 under the Prescription Drug User Fee Act (“PDUFA”) VI program. “The FDA’s acceptance of our BLA for our next-generation neuromodulator product, DAXI,…

Continue Reading

FridayFeb 07, 2020 11:01 am

NetworkNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Founder Discusses Assisting Consumers in Monetizing Their Data in LA Weekly Weekly Podcast

SRAX (NASDAQ: SRAX) founder Chris Miglino was featured in a recent LA Weekly Weekly Podcast with Brian Calle to discuss the topic of big data and SRAX’s capabilities in giving power to the individual. “We created a platform that puts the power of the data back in the hands of the consumer,” Miglino said during the podcast, discussing the company’s platform, which currently amasses 17 million users, to assist consumers in monetizing their data. “So, you as a consumer can own all of your own information and get compensated if a marketer tries to access your data. That platform is…

Continue Reading

FridayFeb 07, 2020 10:26 am

NetworkNewsBreaks – Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF) Enters Electric Snowmobile Sector, Takes Technology Overseas and Partners with Transportation Sector Innovator

Exro Technologies (CSE: XRO) (OTCQB: EXROF) today announced its continued expansion into new market segments through a strategic agreement with one of the world's most innovative manufacturers of snowmobile powertrains. Under the new partnership, Exro and Finland's Aurora Powertrains Oy, which in 2019 released the "eSled" - an all-electric production snowmobile, will work to both increase motor performance while decreasing cost for future production. Exro's technology will be added to the Aurora electric powertrain through the partnership, a further move to global commercialization of Exro technology. “We are very excited to now be entering the snowmobile industry, which sees more…

Continue Reading

FridayFeb 07, 2020 9:47 am

NetworkNewsBreaks – GP Solutions, Inc. (GWPD) Expands Management Team as it Pursues Aggressive Growth Plans

GP Solutions (OTC: GWPD), the developer of "GrowPods" – controlled environment automated micro-farms, today announced that it is adding to its management team and making changes to its Board of Directors. According to the update, the company appointed Christina Kane as its Director of Sales. Kane has extensive business development experience and global manufacturing expertise, having served as director of a major franchise with over 300 stores and established distribution channels in 40+ countries. “Adding Christina to our team will help the company ramp up sales and increase distribution channels,” GP Solutions President George Natzic said in the news release.…

Continue Reading

FridayFeb 07, 2020 9:40 am

NetworkNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) Files Early Warning Report Regarding James E. Wagner Cultivation Corp. (TSX.V: JWCA) (OTCQX: JWCAF) Investment

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, this morning announced that Canopy Rivers Corporation, a wholly owned subsidiary of the company, subscribed for 2,380,952 units of James E. Wagner Cultivation Corp. ("JWC") (TSX.V: JWCA) (OTCQX: JWCAF) at a price of $0.21 each for total consideration of approximately $500,000 in connection with JWC's non-brokered private placement financing. Each unit consists of one common share in the capital of JWC and one-half of one common share purchase warrant. Each warrant enables Canopy Rivers to purchase one common share at any time on or before February 6,…

Continue Reading

ThursdayFeb 06, 2020 3:16 pm

NetworkNewsBreaks – ChineseInvestors.com Inc. (CIIX) Leverages Social Media to Market, Sell New CBD Product

During a recently MoneyTV interview, ChineseInvestors.com (OTCQB: CIIX) CEO Warren Wang announced that the company will be launching a breakthrough CBD product in March. An article discussing the company reads, “One important aspect of the company’s strategy to increase profit is to sell its new CBD product through e-commerce using different social media platforms in 2020. Wang observed that multi-platform social media would play a key role in the company’s marketing to a younger consumer audience of its CBD line. He specifically mentioned using platforms such as TikTok in the campaign, which launched in 2017 and accrued 500 million users…

Continue Reading

ThursdayFeb 06, 2020 3:09 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Providing Alternative to Inhalation via Patented Oral Drug-Delivery Technology

British Columbia-based, biodelivery technology developer Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is committed to the idea that better alternative methods for drug delivery exist than inhalation. A recent article discussing the company reads, “Swallowed medications have historically been slower to provide effective action than inhaled ones, leading substance users looking for a quick fix to lean toward the latter. But the deleterious and deadly consequences of smoking tobacco products have been publicly acknowledged for decades, though hardly stemming the tide of nicotine addiction as one generation succeeds another. . . . The continued preference for the rapid delivery of inhaled…

Continue Reading